Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H. Strand, Graham A. Colditz, Belén Rivero‐Gutiérrez et al.|Cancer Cell|2022Cited by 88
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P. Angus, Gary L. Johnson, Daniel R. Goulet et al.|npj Breast Cancer|2021Cited by 24